Scarica l'app Stockscreener
37.50
7.76%
2.6997
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CORT Giù?
Forum
Previsione
Corcept Therapeutics Inc Borsa (CORT) Ultime notizie
FDA rejects relacorilant for Cushing’s-related high blood pressure - Cushing's Disease News
Corcept Therapeutics (NASDAQ:CORT) Trading Up 9.7%Here's What Happened - MarketBeat
The FDA Just Snubbed Corcept Therapeutics. Should You Buy the Dip in CORT Stock or Stay Far Away - Barchart.com
Implied Volatility Surging for Corcept Stock Options - TradingView — Track All Markets
Canaccord Genuity Adjusts Price Target for Corcept Therapeutics (CORT) | CORT Stock News - GuruFocus
Analysts Offer Insights on Healthcare Companies: Corcept Therapeutics (CORT) and Mind Medicine (MNMD) - The Globe and Mail
Ulta Beauty To Rally Around 16%? Here Are 10 Top Analyst Forecasts For Friday - Benzinga
Corcept Therapeutics (NASDAQ:CORT) Given New $99.00 Price Target at Canaccord Genuity Group - MarketBeat
Corcept Therapeutics stock price target lowered to $90 at H.C. Wainwright - Investing.com UK
Corcept Therapeutics stock price target cut by Canaccord on FDA setback - Investing.com Canada
Corcept Therapeutics (CORT) Faces FDA Setback, But Growth Potent - GuruFocus
HC Wainwright & Co. Lowers Price Target for Corcept Therapeutics (CORT) | CORT Stock News - GuruFocus
US FDA declines to approve Corcept's drug for rare hormonal disorder - Reuters
Kaplan Fox Announces an Investigation Into Corcept Therapeutics, Inc. (CORT) for Potential Securities Law Violations - The National Law Review
Corcept Therapeutics stock tanks on FDA relacorilant setback — what happens next for CORT - ts2.tech
Corcept Therapeutics (CORT) stock sinks after FDA rebuff; relacorilant outlook resets - ts2.tech
A Risky Spot For Corcept Therapeutics (NASDAQ:CORT) - Seeking Alpha
What drives Corcept Therapeutics Incorporated stock priceTrading Psychology Tips & Build Wealth With Strategy - earlytimes.in
FDA says it needs additional evidence of effectiveness for Corcept relacorilant - Yahoo Finance
Stocks making big moves yesterday: FuelCell Energy, Corcept, and PacBio - TradingView — Track All Markets
The Price Is Right For Corcept Therapeutics Incorporated (NASDAQ:CORT) Even After Diving 56% - simplywall.st
Why We're Not Concerned Yet About Corcept Therapeutics Incorporated's (NASDAQ:CORT) 56% Share Price Plunge - 富途牛牛
Corcept Therapeutics stock tanks 50% after FDA relacorilant setback — what’s next for CORT - ts2.tech
Why Corcept Therapeutics plummeted by 50% today - MSN
Why Corcept Therapeutics Plummeted by 50% Today - The Globe and Mail
Corcept stock plunges 50% after FDA rejects relacorilant in Cushing’s-related hypertension - ts2.tech
Why Corcept Therapeutics Plummeted by 50% Today - The Motley Fool
Why Corcept (CORT) Shares Are Falling Today - Finviz
Why Corcept Therapeutics stock crashed today and what comes next? - CryptoRank
Corcept stumbles after Cushing's drug met with FDA rebuff - FirstWord Pharma
Kaplan Fox & Kilsheimer LLP is Investigating Corcept Therapeutics, Inc. (CORT) for Potential Securities Law Violations - NewMediaWire
Corcept Therapeutics price target lowered to $50 from $135 at Truist - TipRanks
Corcept Therapeutics Faces FDA Setback for Relacorilant Approval - TipRanks
Corcept Therapeutics Inc Receives FDA Complete Response Letter for Relacorilant - TradingView — Track All Markets
Corcept Therapeutics (CORT) stock dives nearly 50% after FDA rejects relacorilant — what investors watch next - ts2.tech
Stock Traders Buy Large Volume of Put Options on Corcept Therapeutics (NASDAQ:CORT) - MarketBeat
Truist Securities Lowers Corcept Therapeutics' Price Target to $50 From $135, Buy Rating Kept - marketscreener.com
Truist Securities lowers Corcept Therapeutics stock price target on FDA concerns - Investing.com Nigeria
US FDA declines to approve Corcept’s drug for rare hormonal disorder - WTAQ
Corcept nosedives 48% after FDA rejected core drug - breakingthenews.net
Nasdaq Moves Lower; US Crude Oil Inventories Decline Sharply - Benzinga
Nvidia, Tesla, Nike, DJT, Hecla, Newmont, Corcept, Vanda, and More Market Movers - Barron's
Corcept Therapeutics (CORT) Sees Significant Decline in Stock Va - GuruFocus
Corcept Therapeutics Stock (CORT) Opinions on FDA Rejection of Relacorilant - Quiver Quantitative
Corcept Therapeutics Shares Drop 50% After FDA Rejects Drug - Barron's
Stocks making the biggest moves midday: Nike, Corcept Therapeutics, Taiwan Semiconductor & more - CNBC
Corcept looks to ovarian cancer as relacorilant gets CRL in Cushing - BioWorld MedTech
Corcept Therapeutics (NASDAQ:CORT) Sets New 12-Month Low After Analyst Downgrade - MarketBeat
Nvidia, Tesla, Hecla, Newmont, Nike, Vanda, Corcept, DJT, and More Market Movers - Barron's
Wolfe Research Downgrades Corcept Therapeutics to Underperform from Peer Perform, Price Target is $30 - marketscreener.com
Wolfe Research downgrades Corcept Therapeutics stock rating to Underperform By Investing.com - Investing.com UK
Corcept Therapeutics (CORT) Stock Plummets Over 48% - GuruFocus
FDA rejects Corcept’s cortisol-targeting drug for Cushing’s syndrome - Endpoints News
Corcept Therapeutics stock hits 52-week low at $38.78 By Investing.com - Investing.com Canada
Wolfe Research Downgrades Corcept Therapeutics (NASDAQ:CORT) to Underperform - MarketBeat
Corcept Shares Sink After FDA Rejects Drug to Treat Hypertension - Bloomberg.com
Corcept Therapeutics stock hits 52-week low at $38.78 - Investing.com
Corcept Therapeutics (CORT) Shares Plummet After FDA Rejects Dru - GuruFocus
Why Is Corcept Therapeutics Stock Sinking Wednesday?Corcept Therapeutics (NASDAQ:CORT) - Benzinga
Dow Falls 50 Points; US Initial Jobless Claims Decline - Benzinga
Corcept Therapeutics (CORT) Shares Plummet After FDA Setback - GuruFocus
0.22%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):